Rezolute Inc is a clinical-stage biopharmaceutical company focused on developing therapies for rare and metabolic diseases. The company aims to address unmet medical needs in conditions like congenital hyperinsulinism, a rare endocrine disorder causing excessive insulin production and resulting hypoglycemia. Rezolute’s pipeline includes drug candidates designed to improve patient outcomes while reducing treatment burdens. The company engages in research, development, and clinical trials to advance its therapies and collaborates with medical communities and patient groups to support its objectives. Revenue and value creation depend largely on successful product development and regulatory approvals.
2010
71
Last FY Revenue n/a
Last FY EBITDA -$79.9M
$623M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
In the same period, Rezolute achieved -$83.7M in LTM net income.
See Rezolute valuation multiples based on analyst estimatesIn the most recent fiscal year, Rezolute reported EBITDA of -$79.9M.
Rezolute expects next 12-month revenue of XXX   and NTM EBITDA of XXX
See Rezolute valuation multiples based on analyst estimatesLTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
---|---|---|---|---|---|---|
Revenue | n/a | XXX | n/a | XXX | XXX | XXX |
Gross Profit | n/a | XXX | n/a | XXX | XXX | XXX |
Gross Margin | n/a | XXX | n/a | XXX | XXX | XXX |
EBITDA | n/a | XXX | -$79.9M | XXX | XXX | XXX |
EBITDA Margin | n/a | XXX | n/a | XXX | XXX | XXX |
EBIT | -$88.1M | XXX | -$79.9M | XXX | XXX | XXX |
EBIT Margin | n/a | XXX | n/a | XXX | XXX | XXX |
Net Profit | -$83.7M | XXX | -$74.4M | XXX | XXX | XXX |
Net Margin | n/a | XXX | n/a | XXX | XXX | XXX |
Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Rezolute has current market cap of $789M, and EV of $623M.
As of October 17, 2025, Rezolute's stock price is $9.
See Rezolute trading valuation dataEV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
---|---|---|---|---|---|---|
$623M | $789M | XXX | XXX | XXX | XXX | $-1.00 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialRezolute's trades at n/a EV/Revenue multiple, and -8.3x EV/EBITDA.
See valuation multiples for Rezolute and 15K+ public compsAs of October 17, 2025, Rezolute has market cap of $789M and EV of $623M.
Equity research analysts estimate Rezolute's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Rezolute has a P/E ratio of -9.4x.
LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
---|---|---|---|---|---|---|
Market cap (current) | $789M | XXX | $789M | XXX | XXX | XXX |
EV (current) | $623M | XXX | $623M | XXX | XXX | XXX |
EV/Revenue | n/a | XXX | n/a | XXX | XXX | XXX |
EV/EBITDA | n/a | XXX | -8.3x | XXX | XXX | XXX |
EV/EBIT | -7.1x | XXX | -8.3x | XXX | XXX | XXX |
EV/Gross Profit | n/a | XXX | n/a | XXX | XXX | XXX |
P/E | -9.4x | XXX | -11.0x | XXX | XXX | XXX |
EV/FCF | n/a | XXX | -9.9x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialRezolute's revenue per employee in the last FY averaged n/a, while opex per employee averaged $1.1M for the same period.
Rezolute's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Rezolute's rule of X is n/a (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Rezolute and other 15K+ public compsLTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
---|---|---|---|---|---|---|
Revenue Growth | n/a | XXX | n/a | XXX | XXX | XXX |
EBITDA Margin | n/a | XXX | n/a | XXX | XXX | XXX |
EBITDA Growth | n/a | XXX | n/a | XXX | XXX | XXX |
Rule of 40 | n/a | XXX | n/a | XXX | XXX | XXX |
Bessemer Rule of X | XXX | XXX | n/a | XXX | XXX | XXX |
Revenue per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
Opex per Employee | XXX | XXX | $1.1M | XXX | XXX | XXX |
S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
R&D Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
Opex to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
EV/Revenue | EV/EBITDA | |||||
---|---|---|---|---|---|---|
2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
Armata Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Rezolute acquired XXX companies to date.
Last acquisition by Rezolute was XXXXXXXX, XXXXX XXXXX XXXXXX . Rezolute acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiplesAcquired Company | EV | EV/Revenue | EV/EBITDA |
---|---|---|---|
XXXXXXXXX | XXX | XXX | XXX |
XXXXXXXXX | XXX | XXX | XXX |
XXXXXXXXX | XXX | XXX | XXX |
XXXXXXXXX | XXX | XXX | XXX |
XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 65K+ M&A deals.
Start Free TrialWhen was Rezolute founded? | Rezolute was founded in 2010. |
Where is Rezolute headquartered? | Rezolute is headquartered in United States of America. |
How many employees does Rezolute have? | As of today, Rezolute has 71 employees. |
Who is the CEO of Rezolute? | Rezolute's CEO is Mr. Nevan Charles Elam, J.D.. |
Is Rezolute publicy listed? | Yes, Rezolute is a public company listed on NAS. |
What is the stock symbol of Rezolute? | Rezolute trades under RZLT ticker. |
When did Rezolute go public? | Rezolute went public in 2011. |
Who are competitors of Rezolute? | Similar companies to Rezolute include e.g. Julphar, Galapagos, Pharming, Vivoryon Therapeutics. |
What is the current market cap of Rezolute? | Rezolute's current market cap is $789M |
Is Rezolute profitable? | Yes, Rezolute is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.